Your browser doesn't support javascript.
loading
The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer.
Mattox, Austin K; Douville, Christopher; Wang, Yuxuan; Popoli, Maria; Ptak, Janine; Silliman, Natalie; Dobbyn, Lisa; Schaefer, Joy; Lu, Steve; Pearlman, Alexander H; Cohen, Joshua D; Tie, Jeanne; Gibbs, Peter; Lahouel, Kamel; Bettegowda, Chetan; Hruban, Ralph H; Tomasetti, Cristian; Jiang, Peiyong; Chan, K C Allen; Lo, Yuk Ming Dennis; Papadopoulos, Nickolas; Kinzler, Kenneth W; Vogelstein, Bert.
Afiliação
  • Mattox AK; Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Douville C; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Wang Y; The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Popoli M; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Ptak J; Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Silliman N; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Dobbyn L; The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Schaefer J; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Lu S; Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Pearlman AH; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Cohen JD; The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Tie J; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Gibbs P; Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Lahouel K; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Bettegowda C; The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Hruban RH; Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Tomasetti C; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Jiang P; The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Chan KCA; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Lo YMD; Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Papadopoulos N; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Kinzler KW; The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Vogelstein B; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Cancer Discov ; 13(10): 2166-2179, 2023 10 05.
Article em En | MEDLINE | ID: mdl-37565753
ABSTRACT
Cell-free DNA (cfDNA) concentrations from patients with cancer are often elevated compared with those of healthy controls, but the sources of this extra cfDNA have never been determined. To address this issue, we assessed cfDNA methylation patterns in 178 patients with cancers of the colon, pancreas, lung, or ovary and 64 patients without cancer. Eighty-three of these individuals had cfDNA concentrations much greater than those generally observed in healthy subjects. The major contributor of cfDNA in all samples was leukocytes, accounting for ∼76% of cfDNA, with neutrophils predominating. This was true regardless of whether the samples were derived from patients with cancer or the total plasma cfDNA concentration. High levels of cfDNA observed in patients with cancer did not come from either neoplastic cells or surrounding normal epithelial cells from the tumor's tissue of origin. These data suggest that cancers may have a systemic effect on cell turnover or DNA clearance.

SIGNIFICANCE:

The origin of excess cfDNA in patients with cancer is unknown. Using cfDNA methylation patterns, we determined that neither the tumor nor the surrounding normal tissue contributes this excess cfDNA-rather it comes from leukocytes. This finding suggests that cancers have a systemic impact on cell turnover or DNA clearance. See related commentary by Thierry and Pisareva, p. 2122. This article is featured in Selected Articles from This Issue, p. 2109.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Colorretais / Ácidos Nucleicos Livres Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Colorretais / Ácidos Nucleicos Livres Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article